1129OStage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. (23rd October 2018) - Leal, T A; Spira, A I; Blakely, C; He, K; Berz, D; Richards, D; Uyeki, J; Savage, A; Roque, T; Massarelli, E; Jotte, R M; Chen, I; et al.